Loading...
0
New

Cardiac Biomarkers Testing Market by Type (Myocardial Muscle Creatine Kinase, Troponins, Myoglobin, Brain Natriuretic Peptide, Ischemia-modified Albumin, and Others), Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, and Others) and Location of Testing (Point of care Testing and Laboratory Testing): Global Opportunity Analysis and Industry Forecast, 2019–2026

LI_195284
Pages: 256
May 2019 | 815 Views
 
Author(s) : Tenzin Kunsel , Onkar Sumant
Tables: 137
Charts: 51
 

Cardiac Biomarkers Testing Market Outlook - 2026

Cardiac biomarkers are the substances released into the blood stream from the damaged muscle of the heart. These biomarkers are used to diagnose heart functioning, risk stratifications, and cardiac diseases in patients. Biomarker is a quantifiable and measurable biological parameter that includes an enzyme, hormones, and proteins, all associated with heart function, failure, or damage. The global cardiac biomarkers testing market size was $7,638 million in 2018, and is projected to reach $18,232 million by 2026, growing at a CAGR of 11.4% from 2019 to 2026.

Cardiac biomarkers are used in monitoring progress of treatments such as diagnostic & prognostic purposes and to measure the impact of treatments on diseases. This monitoring system, based on cardiac biomarkers, influences researchers to develop new therapies and enables clinicians to conduct therapeutic treatments noninvasively. Cardiac biomarkers are used in combination with analyzer systems to monitor and control the treatment procedures. Moreover, they enable surgeons to measure the efficiency of therapy by providing accurate information about heart. They are further used to identify the presence of acute heart conditions at the earliest, so as to initiate an appropriate treatment. Cardiac biomarker testing is expected to be among the fastest growing segment in the overall cardiology market.

Global Cardiac Biomarkers Testing Market

Get more information on this report : Request Sample Pages

The progress of healthcare toward personalized medicine has increased the importance of cardiac biomarkers for efficient, quick, and quality maintenance of health. Implementation of stringent regulations by the FDA for biomarker tests and assays that can be used for detection of any cardiac disorder  and establishment of proper biomarker applications have helped the key players to invest in the production of various cardiac biomarkers. The key market players such as Roche Diagnostic, Abbott Laboratories, and others are developing and actively commercializing their products by incorporating various innovative technologies. In addition, rise in trend of point-of-care testing (POCT) due to increased government focus on reducing the length of stay of patients and various mode of patient care such as homecare, emergency room, and near patient testing is driving the growth of the global cardiac biomarkers testing market size.

Increase in awareness about the importance of early diagnosis and rise in need for prevention of cardiac diseases such as heart failure, heart attack, ACS, and others are the major factors that have contributed toward the growth of the global cardiac biomarkers testing market. Moreover, increase in survival rate of cardiac patients by diagnosing cardiac disease quickly and accurately boosts the cardiac biomarkers testing market. In addition, advancements in healthcare facilities and active initiation for prevention of cardiac disease across developing countries significantly propel the growth of the global market.

Global Cardiac Biomarkers Testing Market By Type

Get more information on this report : Request Sample Pages

Type segment review

The global cardiac biomarkers testing market is segmented based on type, application, location of testing, and region. Depending on type, the cardiac biomarkers testing market is categorized into creatine kinase (CK-MB), troponins T & I, myoglobin, BNPs, IMA, and others. The troponins segment was the highest revenue generator in the global cardiac biomarkers testing market in 2018, due to its prodigious specificity and its ability to accurately detect the cardiac events of acute coronary syndrome, MI, and other cardiac injuries. However, the IMA segment is expected to grow at high CAGR, as IMA biomarkers improve the sensitivity and negative predictive value for the diagnosis of myocardial ischemia when used in combination with standard cardiac biomarkers.

Global Cardiac Biomarkers Testing Market By Application

Get more information on this report : Request Sample Pages

Application segment review

Based on applications, the cardiac biomarkers testing market is segmented into myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis, and others. Myocardial infarction held the highest share in the global cardiac biomarkers testing market in 2018, due to its high prevalence rate as compared to all other cardiovascular diseases (CVDs). Moreover, MI is among the leading cause of mortality and morbidity worldwide. Hence, many patients use cardiac biomarkers for early diagnosis of MI. However, congestive heart failure segment is expected to grow at the highest rate, owing to increase in demand for biomarker tests for early detection of heart failure.

Global Cardiac Biomarkers Testing Market By Region

Get more information on this report : Request Sample Pages

Region segment review

Region wise, the cardiac biomarkers testing market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America leads the global market, owing to high demand for cardiac testing, high CVD prevalence rate, and increase in awareness toward cardiac diagnostics solutions. Moreover, intensive efforts taken by government and research institutes to deal with critical cardiac diseases and increase in R&D activities related to cardiac biomarkers boost the market growth in North America. However, Asia-Pacific is expected to grow at the highest CAGR during the cardiac biomarkers testing market forecast period, due to surge in disposable income and rise in affordability for advanced cardiac treatments. Furthermore, increase in interest of research-based pharmaceutical companies to develop novel biomarkers and rise in number of patients suffering from cardiovascular diseases are anticipated to fuel the market growth in Asia-Pacific.

The report provides a comprehensive analysis of the key players operating in the global cardiac biomarkers testing market. These players are Roche Diagnostics, Abbott Laboratories, Siemens Healthcare, Becton, Dickinson and Company, Bio-Rad Laboratories, BioMerieux, PerkinElmer Inc., Tosoh Corporation, Danaher Corporation, and Thermo Fisher Scientific.

The other players operating in the global cardiac biomarkers testing market include Randox Laboratories, Johnson and Johnson, Olympus Corporation, BG Medicines, ACS Biomarker B.V., and Cavadis Biomedical.

Key Benefits for Cardiac Biomarkers Testing Market:

  • This report provides a detailed quantitative analysis of the current cardiac biomarkers testing market trends and future estimations from 2019 to 2026, which assists to identify the prevailing market opportunities.
  • An in-depth cardiac biomarkers testing market analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.
  • A comprehensive analysis of the factors that drive and restrain the growth of the global cardiac biomarkers testing market is provided.
  • An extensive analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves.

Cardiac Biomarkers Testing Key Market Segments:

By Type

  • Myocardial Muscle Creatine Kinase (CK-MB)
  • Troponins (T and I)
  • Myoglobin
  • Brain Natriuretic Peptide (BNPs) or NT-proBNP
  • Ischemia-modified Albumin (IMA)
  • Others

By Application

  • Myocardial Infarction
  • Congestive Heart Failure
  • Acute Coronary Syndrome
  • Atherosclerosis
  • Others

By Location of Testing

  • Point of Care Testing
  • Laboratory Testing

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Rest of Europe
  • Asia-Pacific
    • Australia
    • Japan
    • India
    • China
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle East
    • Africa
 

CHAPTER 1:    INTRODUCTION

1.1.    Report description
1.2.    Key benefits for stakeholders
1.3.    Key market segments
1.4.    Research methodology

1.4.1.    Secondary research
1.4.2.    Primary research
1.4.3.    Analyst tools & models

CHAPTER 2:    EXECUTIVE SUMMARY

2.1.    Key findings

2.1.1.    Top impacting factors
2.1.2.    Top investment pockets

2.2.    CXO perspective

CHAPTER 3:    MARKET OVERVIEW

3.1.    Market definition and scope
3.2.    Biomarker diagnosis vs. conventional diagnosis
3.3.    Assessment of key advantages and buying criteria for diagnostic biomarkers

3.3.1.    Early diagnosis
3.3.2.    Tissue specific diagnosis
3.3.3.    Reduce clinical trials
3.3.4.    Consistent output

3.4.    Key trends impacting the Cardiac biomarker testing market

3.4.1.    Development of high sensitive biomarkers for risk stratification
3.4.2.    Technological advancements in the cardiac biomarkers: Serum based biomarkers
3.4.3.    Increasing demand for point of care cardiac diagnostics

3.5.    Parent Market Overview
3.6.    Key Forces Shaping Cardiac biomarker testing market

3.6.1.    High bargaining power of suppliers
3.6.2.    Low bargaining power of buyers
3.6.3.    Low threat of new entrants
3.6.4.    Low threat of substitutes
3.6.5.    High intensity of rivalry

3.7.    Value chain analysis
3.8.    Pricing Analysis

3.8.1.    Pricing Analysis, By Region, 2018 & 2025

3.9.    Market evolution/Industry roadmap
3.10.    Government regulations
3.11.    Reimbursement issues
3.12.    Patent Analysis

3.12.1.    By Region (2016-2018)
3.12.2.    By Applicant

3.13.    Market share analysis
3.14.    Case Studies

3.14.1.    Case Study

3.15.    Market dynamics

3.15.1.    Drivers

3.15.1.1.    Increasing prevalence of cardiovascular diseases
3.15.1.2.    Cost effective
3.15.1.3.    Non-invasive
3.15.1.4.    Accuracy prediction
3.15.1.5.    Technological advancements using cardiac biomarkers combinations
3.15.1.6.    Increasing point of care (POC) testing

3.15.2.    Restraints

3.15.2.1.    Government Regulation
3.15.2.2.    Conformation in result
3.15.2.3.    Complex process

3.15.3.    Opportunities

3.15.3.1.    Personalized medicine
3.15.3.2.    Point of care (POCT) testing using cardiac biomarkers

CHAPTER 4:    CARDIAC BIOMARKER TESTING MARKET, BY TYPE

4.1.    Overview

4.1.1.    Market size and forecast

4.2.    Creatine kinase (CK-MB)

4.2.1.    Key market trends and opportunities
4.2.2.    Market size and forecast
4.2.3.    Market analysis, by country

4.3.    Troponins

4.3.1.    Key market trends and opportunities
4.3.2.    Market size and forecast
4.3.3.    Market analysis, by country

4.4.    Myoglobin

4.4.1.    Key market trends and opportunities
4.4.2.    Market size and forecast
4.4.3.    Market analysis, by country

4.5.    Natriuretic peptides (BNP and NT-proBNP)

4.5.1.    Key market trends and opportunities
4.5.2.    Market size and forecast
4.5.3.    Market analysis, by country

4.6.    Ischemia modified albumin

4.6.1.    Key market trends and opportunities
4.6.2.    Market size and forecast
4.6.3.    Market analysis, by country

4.7.    Others

4.7.1.    Key market trends and opportunities
4.7.2.    Market size and forecast
4.7.3.    Market analysis, by country

CHAPTER 5:    CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION

5.1.    Overview

5.1.1.    Market size and forecast

5.2.    Myocardial infarction

5.2.1.    Market size and forecast
5.2.2.    Market analysis, by country

5.3.    Congestive heart failure

5.3.1.    Market size and forecast
5.3.2.    Market analysis, by country

5.4.    Acute coronary syndrome

5.4.1.    Market size and forecast
5.4.2.    Market analysis, by country

5.5.    Atherosclerosis

5.5.1.    Market size and forecast
5.5.2.    Market analysis, by country

5.6.    Other applications

5.6.1.    Market size and forecast
5.6.2.    Market analysis, by country

CHAPTER 6:    CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING

6.1.    Overview

6.1.1.    Market size and forecast

6.2.    Point of care testing

6.2.1.    Market size and forecast
6.2.2.    Market analysis, by country

6.3.    Laboratory testing

6.3.1.    Market size and forecast
6.3.2.    Market analysis, by country

CHAPTER 7:    CARDIAC BIOMARKER TESTING MARKET, BY REGION

7.1.    Overview

7.1.1.    Market size and forecast

7.2.    North America

7.2.1.    Key market trends and opportunities
7.2.2.    North America market size and forecast, by type
7.2.3.    North America market size and forecast, by application
7.2.4.    North America market size and forecast, by location of testing
7.2.5.    North America market size and forecast, by country

7.2.5.1.    U.S.

7.2.5.1.1.    U.S. market size and forecast, by type
7.2.5.1.2.    U.S. market size and forecast, by application
7.2.5.1.3.    U.S. market size and forecast, by location of testing

7.2.5.2.    Canada

7.2.5.2.1.    Canada market size and forecast, by type
7.2.5.2.2.    Canada market size and forecast, by application
7.2.5.2.3.    Canada market size and forecast, by location of testing

7.2.5.3.    Mexico

7.2.5.3.1.    Mexico market size and forecast, by type
7.2.5.3.2.    Mexico market size and forecast, by application
7.2.5.3.3.    Mexico market size and forecast, by location of testing

7.3.    Europe

7.3.1.    Key market trends and opportunities
7.3.2.    Europe market size and forecast, by type
7.3.3.    Europe market size and forecast, by application
7.3.4.    Europe market size and forecast, by location of testing
7.3.5.    Europe market size and forecast, by country

7.3.5.1.    UK

7.3.5.1.1.    UK market size and forecast, by type
7.3.5.1.2.    UK market size and forecast, by application
7.3.5.1.3.    UK market size and forecast, by location of testing

7.3.5.2.    France

7.3.5.2.1.    France market size and forecast, by type
7.3.5.2.2.    France market size and forecast, by application
7.3.5.2.3.    France market size and forecast, by location of testing

7.3.5.3.    Germany

7.3.5.3.1.    Germany market size and forecast, by type
7.3.5.3.2.    Germany market size and forecast, by application
7.3.5.3.3.    Germany market size and forecast, by location of testing

7.3.5.4.    Rest of Europe

7.3.5.4.1.    Rest of Europe market size and forecast, by type
7.3.5.4.2.    Rest of Europe market size and forecast, by application
7.3.5.4.3.    Rest of Europe market size and forecast, by location of testing

7.4.    Asia-Pacific

7.4.1.    Key market trends and opportunities
7.4.2.    Asia-Pacific market size and forecast, by type
7.4.3.    Asia-Pacific market size and forecast, by application
7.4.4.    Asia-Pacific market size and forecast, by location of testing
7.4.5.    Asia-Pacific market size and forecast, by country

7.4.5.1.    China

7.4.5.1.1.    China market size and forecast, by type
7.4.5.1.2.    China market size and forecast, by application
7.4.5.1.3.    China market size and forecast, by location of testing

7.4.5.2.    India

7.4.5.2.1.    India market size and forecast, by type
7.4.5.2.2.    India market size and forecast, by application
7.4.5.2.3.    India market size and forecast, by location of testing

7.4.5.3.    Australia

7.4.5.3.1.    Australia market size and forecast, by type
7.4.5.3.2.    Australia market size and forecast, by application
7.4.5.3.3.    Australia market size and forecast, by location of testing

7.4.5.4.    Japan

7.4.5.4.1.    Japan market size and forecast, by type
7.4.5.4.2.    Japan market size and forecast, by application
7.4.5.4.3.    Japan market size and forecast, by location of testing

7.4.5.5.    Rest of Asia-Pacific

7.4.5.5.1.    Rest of Asia-Pacific market size and forecast, by type
7.4.5.5.2.    Rest of Asia-Pacific market size and forecast, by application
7.4.5.5.3.    Rest of Asia-Pacific market size and forecast, by location of testing

7.5.    LAMEA

7.5.1.    Key market trends and opportunities
7.5.2.    LAMEA market size and forecast, by type
7.5.3.    LAMEA market size and forecast, by application
7.5.4.    LAMEA market size and forecast, by location of testing
7.5.5.    LAMEA market size and forecast, by country

7.5.5.1.    Latin America

7.5.5.1.1.    Latin America market size and forecast, by type
7.5.5.1.2.    Latin America market size and forecast, by application
7.5.5.1.3.    Latin America market size and forecast, by location of testing

7.5.5.2.    Middle East

7.5.5.2.1.    Middle East market size and forecast, by type
7.5.5.2.2.    Middle East market size and forecast, by application
7.5.5.2.3.    Middle East market size and forecast, by location of testing

7.5.5.3.    Africa

7.5.5.3.1.    Africa market size and forecast, by type
7.5.5.3.2.    Africa market size and forecast, by application
7.5.5.3.3.    Africa market size and forecast, by location of testing

CHAPTER 8:    COMPANY PROFILES

8.1.    Abbott Laboratories

8.1.1.    Company overview
8.1.2.    Company snapshot
8.1.3.    Operating business segments
8.1.4.    Product portfolio
8.1.5.    Business performance
8.1.6.    Key strategic moves and developments

8.2.    Becton, Dickinson and Company

8.2.1.    Company overview
8.2.2.    Company snapshot
8.2.3.    Operating business segments
8.2.4.    Product portfolio
8.2.5.    Business performance

8.3.    BioMerieux

8.3.1.    Company overview
8.3.2.    Company snapshot
8.3.3.    Operating business segments
8.3.4.    Business performance

8.4.    Bio-Rad Laboratories, Inc.

8.4.1.    Company overview
8.4.2.    Company snapshot
8.4.3.    Operating business segments
8.4.4.    Business performance

8.5.    Danaher Corporation

8.5.1.    Company overview
8.5.2.    Company snapshot
8.5.3.    Operating business segments
8.5.4.    Business performance

8.6.    F. HOFFMANN-LA ROCHE LTD.

8.6.1.    Company overview
8.6.2.    Company snapshot
8.6.3.    Operating business segments
8.6.4.    Business performance

8.7.    Siemens AG

8.7.1.    Company overview
8.7.2.    Company snapshot
8.7.3.    Operating business segments
8.7.4.    Business performance

8.8.    Thermo Fisher Scientific, Inc.

8.8.1.    Company overview
8.8.2.    Company snapshot
8.8.3.    Operating business segments
8.8.4.    Business performance

8.9.    PerkinElmer Inc.

8.9.1.    Company overview
8.9.2.    Company snapshot
8.9.3.    Operating business segments
8.9.4.    Business performance

8.10.    Tosoh Corporation

8.10.1.    Company overview
8.10.2.    Company snapshot
8.10.3.    Operating business segments
8.10.4.    Business performance

LIST OF TABLES

TABLE 01.    CONVENTIONAL DIAGNOSTICS VERSUS DIAGNOSTIC BIOMARKER TECHNIQUES
TABLE 02.    CASE STUDY
TABLE 03.    APPLICATIONS AND BENEFITS OF POINT OF CARE TESTING
TABLE 04.    CARDIAC BIOMARKERS FOR CVD IN TNT
TABLE 05.    CHARACTERISTICS OF CARDIAC BIOMARKER
TABLE 06.    GLOBAL CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 07.    CARDIAC BIOMARKER TESTING MARKET FOR CREATINE KINASE, BY REGION, 2018–2026 ($MILLION)
TABLE 08.    CARDIAC BIOMARKER TESTING MARKET FOR ARTHROSPIRA MAXIMA, BY REGION, 2018–2026 ($MILLION)
TABLE 09.    CARDIAC BIOMARKER TESTING MARKET FOR MYOGLOBIN, BY REGION, 2018–2026 ($MILLION)
TABLE 10.    CARDIAC BIOMARKER TESTING MARKET FOR NATRIURETIC PEPTIDES (BNP AND NT-PROBNP), BY REGION, 2018–2026 ($MILLION)
TABLE 11.    CARDIAC BIOMARKER TESTING MARKET FOR ISCHEMIA MODIFIED ALBUMIN, BY REGION, 2018–2026 ($MILLION)
TABLE 12.    CARDIAC BIOMARKER TESTING MARKET FOR OTHERS, BY REGION, 2018–2026 ($MILLION)
TABLE 13.    GLOBAL CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 14.    CARDIAC BIOMARKERS USED FOR MONITORING PATIENTS WITH MYOCARDIAL INFRACTIONS
TABLE 15.    CARDIAC BIOMARKER TESTING MARKET FOR MYOCARDIAL INFARCTION, BY REGION, 2018–2026, ($MILLION)
TABLE 16.    CARDIAC BIOMARKER TESTING MARKET FOR CONGESTIVE HEART FAILURE, BY REGION, 2018–2026, ($MILLION)
TABLE 17.    CARDIAC BIOMARKER TESTING MARKET FOR ACUTE CORONARY SYNDROME, BY REGION, 2018–2026, ($MILLION)
TABLE 18.    CARDIAC BIOMARKER TESTING MARKET FOR ATHEROSCLEROSIS, BY REGION, 2018–2026, ($MILLION)
TABLE 19.    CARDIAC BIOMARKER TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2018–2026, ($MILLION)
TABLE 20.    GLOBAL CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 21.    CARDIAC BIOMARKER TESTING MARKET FOR POINT OF CARE TESTING, BY REGION, 2018–2026, ($MILLION)
TABLE 22.    CARDIAC BIOMARKER TESTING MARKET FOR LABORATORY TESTING, BY REGION, 2018–2026, ($MILLION)
TABLE 23.    CARDIAC BIOMARKER TESTING MARKET, BY REGION, 2018–2026, ($MILLION)
TABLE 24.    NORTH AMERICA CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 25.    NORTH AMERICA CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 26.    NORTH AMERICA CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 27.    NORTH AMERICA CARDIAC BIOMARKER TESTING MARKET, BY COUNTRY, 2018–2026, ($MILLION)
TABLE 28.    U.S. CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 29.    U.S. CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 30.    U.S. CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 31.    CANADA CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 32.    CANADA CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 33.    CANADA CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 34.    MEXICO CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 35.    MEXICO CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 36.    MEXICO CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 37.    EUROPE CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 38.    EUROPE CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 39.    EUROPE CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 40.    EUROPE CARDIAC BIOMARKER TESTING MARKET, BY COUNTRY, 2018–2026, ($MILLION)
TABLE 41.    UK CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 42.    UK CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 43.    UK CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 44.    FRANCE CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 45.    FRANCE CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 46.    FRANCE CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 47.    GERMANY CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 48.    GERMANY CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 49.    GERMANY CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 50.    REST OF EUROPE CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 51.    REST OF EUROPE CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 52.    REST OF EUROPE CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 53.    ASIA-PACIFIC CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 54.    ASIA-PACIFIC CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 55.    ASIA-PACIFIC CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 56.    ASIA-PACIFIC CARDIAC BIOMARKER TESTING MARKET, BY COUNTRY, 2018–2026, ($MILLION)
TABLE 57.    CHINA CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 58.    CHINA CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 59.    CHINA CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 60.    INDIA CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 61.    INDIA CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 62.    INDIA CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 63.    AUSTRALIA CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 64.    AUSTRALIA CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 65.    AUSTRALIA CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 66.    JAPAN CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 67.    JAPAN CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 68.    JAPAN CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 69.    REST OF ASIA-PACIFIC CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 70.    REST OF ASIA-PACIFIC CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 71.    REST OF ASIA-PACIFIC CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 72.    LAMEA CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 73.    LAMEA CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 74.    LAMEA CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 75.    LAMEA CARDIAC BIOMARKER TESTING MARKET, BY COUNTRY, 2018–2026, ($MILLION)
TABLE 76.    LATIN AMERICA CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 77.    LATIN AMERICA CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 78.    LATIN AMERICA CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 79.    MIDDLE EAST CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 80.    MIDDLE EAST CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 81.    MIDDLE EAST CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 82.    AFRICA CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 83.    AFRICA CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 84.    AFRICA CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 85.    ABBOTT: COMPANY SNAPSHOT
TABLE 86.    ABBOTT: OPERATING SEGMENTS
TABLE 87.    ABBOTT: PRODUCT PORTFOLIO
TABLE 88.    BD: COMPANY SNAPSHOT
TABLE 89.    BD: OPERATING SEGMENTS
TABLE 90.    BD: PRODUCT PORTFOLIO
TABLE 91.    BIOMÉRIEUX, INC.: COMPANY SNAPSHOT
TABLE 92.    BIOMÉRIEUX, INC.: OPERATING SEGMENTS
TABLE 93.    BIO-RAD: COMPANY SNAPSHOT
TABLE 94.    BIO-RAD: OPERATING SEGMENTS
TABLE 95.    DANAHER: COMPANY SNAPSHOT
TABLE 96.    DANAHER: OPERATING SEGMENTS
TABLE 97.    ROCHE: COMPANY SNAPSHOT
TABLE 98.    ROCHE: OPERATING SEGMENTS
TABLE 99.    SEIMENS: COMPANY SNAPSHOT
TABLE 100.    SEIMENS: PRODUCT SEGMENTS
TABLE 101.    THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
TABLE 102.    THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS
TABLE 103.    PERKINELMER: COMPANY SNAPSHOT
TABLE 104.    PERKINELMER: OPERATING SEGMENTS
TABLE 105.    TOSOH: COMPANY SNAPSHOT
TABLE 106.    TOSOH: OPERATING SEGMENTS

LIST OF FIGURES

FIGURE 01.    TOP IMPACTING FACTORS, 2018-2026
FIGURE 02.    TOP INVESTMENT POCKETS, 2018
FIGURE 03.    PARENT MARKET
FIGURE 04.    VALUE CHAIN ANALYSIS OF GLOBAL CARDIAC BIOMARKERS
FIGURE 05.    PRICING ANALYSIS, BY REGION, 2018 & 2025
FIGURE 06.    PATENT ANALYSIS, BY REGION
FIGURE 07.    PATENT ANALYSIS, BY APPLICANT
FIGURE 08.    MARKET SHARE ANALYSIS, 2018
FIGURE 09.    COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR CREATINE KINASE, BY COUNTRY,  2018 & 2026 (%)
FIGURE 10.    COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR ARTHROSPIRA MAXIMA, BY COUNTRY,  2018 & 2026 (%)
FIGURE 11.    COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR MYOGLOBIN, BY COUNTRY,  2018 & 2026 (%)
FIGURE 12.    COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR NATRIURETIC PEPTIDES (BNP AND NT-PROBNP), BY COUNTRY,  2018 & 2026 (%)
FIGURE 13.    COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR ISCHEMIA MODIFIED ALBUMIN, BY COUNTRY,  2018 & 2026 (%)
FIGURE 14.    COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR OTHERS, BY COUNTRY,  2018 & 2026 (%)
FIGURE 15.    COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR NUTRACEUTICALS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 16.    COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR CONGESTIVE HEART FAILURE, BY COUNTRY, 2018 & 2026 (%)
FIGURE 17.    COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR ACUTE CORONARY SYNDROME, BY COUNTRY,  2018 & 2026 (%)
FIGURE 18.    COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR ATHEROSCLEROSIS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 19.    COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY,  2018 & 2026 (%)
FIGURE 20.    COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR POINT OF CARE TESTING, BY COUNTRY, 2018 & 2026 (%)
FIGURE 21.    COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR LABORATORY TESTING, BY COUNTRY, 2018 & 2026 (%)
FIGURE 22.    ABBOTT: NET SALES, 2016–2018 ($MILLION)
FIGURE 23.    ABBOTT: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 24.    ABBOTT: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 25.    BD: NET SALES, 2015–2017 ($MILLION)
FIGURE 26.    BD: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 27.    BD: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 28.    BIOMÉRIEUX, INC.: REVENUE, 2015–2017 ($MILLION)
FIGURE 29.    BIOMÉRIEUX, INC.: REVENUE SHARE BY APPLICATION, 2017 (%)
FIGURE 30.    BIOMÉRIEUX, INC.: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 31.    BIO-RAD: NET SALES, 2016–2018 ($MILLION)
FIGURE 32.    BIO-RAD: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 33.    BIO-RAD: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 34.    DANAHER: NET SALES, 2016–2018 ($MILLION)
FIGURE 35.    DANAHER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 36.    DANAHER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 37.    ROCHE: NET SALES, 2016–2018 ($MILLION)
FIGURE 38.    ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 39.    ROCHE: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 40.    SEIMENS: NET SALES, 2016–2018 ($MILLION)
FIGURE 41.    SEIMENS: REVENUE SHARE BY PRODUCT SEGMENT, 2018 (%)
FIGURE 42.    SEIMENS: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 43.    THERMO FISHER SCIENTIFIC: REVENUE, 2016–2018 ($MILLION)
FIGURE 44.    THERMO FISHER SCIENTIFIC: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 45.    THERMO FISHER SCIENTIFIC: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 46.    PERKINELMER: NET SALES, 2016–2018 ($MILLION)
FIGURE 47.    PERKINELMER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 48.    PERKINELMER: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 49.    TOSOH: NET SALES, 2016–2018 ($MILLION)
FIGURE 50.    TOSOH: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 51.    TOSOH: REVENUE SHARE BY REGION, 2018 (%)

 
 

Development of novel and advanced cardiac biomarkers such as, troponin T and I that would help in early detection of cardiac disorders is a major factor that boosts the market growth for cardiac biomarkers. This has increased the adoption of cardiac biomarkers across the world. Decrease in the cost of medical devices and increase in awareness for early diagnosis & prognosis of cardiac diseases have offered lucrative opportunities for the growth of the cardiac biomarkers market. Moreover, cardiac biomarkers find their application in list of chronic to mid cardiovascular conditions, which fuel their adoption across the globe, thereby propelling the market growth.

The development of biomarker protein that detects abnormal heart condition before the occurrence of conditions provides remunerative opportunities for the investors. Investors of the cardiac biomarker industry are now focusing on commercialization of cardiac biomarkers with most efficiency. This growing interest of investors in developing more efficient biomarkers has negatively impacted the R&D activities for conventional biomarkers such as CK-MB. However, the combinational application of conventional cardiac biomarkers such as troponin with myoglobin has maintained the market share for conventional biomarkers.

The demand for cardiac biomarkers in terms of point of care testing is increasing rapidly, owing to their easy operational features. Currently, developed regions are witnessing heavy adoption of cardiac biomarkers, owing to the presence of structured healthcare reimbursement and increase in awareness for early disease diagnosis. However, the patient population in developing regions are unaware about the commercial presence of such biomarkers. On the contrary, rise in awareness toward cardiac biomarkers and active interventions pertaining to novel cardiac biomarkers boost the market growth.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry

Download Sample

Request Customization

Download Sample

OR

Purchase Full Report of
Cardiac Biomarkers Testing Market

  • Online Only
  • $3456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3840
  • Restricted to one authorized user
  • One print only
  • Available in Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5370
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8995
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

FREQUENTLY ASKED
QUESTIONS?

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 
Download Sample

Buy Full Version
"Cardiac Biomarkers Testing Market"
Purchase Enquiry